azenosertib
Phase 2Recruiting 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Conditions
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Trial Timeline
Feb 17, 2022 → Jun 30, 2027
NCT ID
NCT05128825About azenosertib
azenosertib is a phase 2 stage product being developed by Zentalis Pharmaceuticals for High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05128825. Target conditions include High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Hype Score Breakdown
Clinical
12
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05128825 | Phase 2 | Recruiting |
| NCT04814108 | Phase 2 | Completed |
| NCT04158336 | Phase 1 | Completed |
Competing Products
8 competing products in High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sepantronium Bromide | Cothera Bioscience | Phase 2 | 29 |
| Mirvetuximab Soravtansine | AbbVie | Phase 2 | 42 |
| Pembrolizumab + Paclitaxel + Carboplatin + Avastin + MK-4830 + Docetaxel | Merck | Phase 2 | 35 |
| BMS-986463 | Bristol Myers Squibb | Phase 1 | 36 |
| Mebendazole | Brain Biotech | Phase 1 | 19 |
| Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells | Brain Biotech | Phase 1 | 23 |
| APR-246 + Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD) | Aprea Therapeutics | Phase 1/2 | 22 |
| APR-246 + Pegylated Liposomal Doxorubicin Hydrochloride (PLD) | Aprea Therapeutics | Phase 2 | 25 |